Disease modification in OA - will we ever get there?

L Stefan Lohmander, Ewa M Roos

Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

Resumé

No drugs are currently approved that change the natural course of osteoarthritis (OA) and translate to long-term, clinically relevant benefits. Two-stage clinical trial designs for OA have now received FDA approval, but remaining challenges lie in defining suitable study populations, surrogate outcomes and pivotal long-term, clinically relevant trial endpoints.

OriginalsprogEngelsk
TidsskriftNature Reviews. Rheumatology
Vol/bind15
Udgave nummer3
Sider (fra-til)133-135
ISSN1759-4790
DOI
StatusUdgivet - mar. 2019

Fingeraftryk

Clinical Trials
Pharmaceutical Preparations
Population

Citer dette

Lohmander, L Stefan ; Roos, Ewa M. / Disease modification in OA - will we ever get there?. I: Nature Reviews. Rheumatology. 2019 ; Bind 15, Nr. 3. s. 133-135.
@article{493c240046054b109ae8ca27d996f0c2,
title = "Disease modification in OA - will we ever get there?",
abstract = "No drugs are currently approved that change the natural course of osteoarthritis (OA) and translate to long-term, clinically relevant benefits. Two-stage clinical trial designs for OA have now received FDA approval, but remaining challenges lie in defining suitable study populations, surrogate outcomes and pivotal long-term, clinically relevant trial endpoints.",
author = "Lohmander, {L Stefan} and Roos, {Ewa M}",
year = "2019",
month = "3",
doi = "10.1038/s41584-019-0174-1",
language = "English",
volume = "15",
pages = "133--135",
journal = "Nature Reviews. Rheumatology",
issn = "1759-4790",
publisher = "Nature Publishing Group",
number = "3",

}

Disease modification in OA - will we ever get there? / Lohmander, L Stefan; Roos, Ewa M.

I: Nature Reviews. Rheumatology, Bind 15, Nr. 3, 03.2019, s. 133-135.

Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

TY - JOUR

T1 - Disease modification in OA - will we ever get there?

AU - Lohmander, L Stefan

AU - Roos, Ewa M

PY - 2019/3

Y1 - 2019/3

N2 - No drugs are currently approved that change the natural course of osteoarthritis (OA) and translate to long-term, clinically relevant benefits. Two-stage clinical trial designs for OA have now received FDA approval, but remaining challenges lie in defining suitable study populations, surrogate outcomes and pivotal long-term, clinically relevant trial endpoints.

AB - No drugs are currently approved that change the natural course of osteoarthritis (OA) and translate to long-term, clinically relevant benefits. Two-stage clinical trial designs for OA have now received FDA approval, but remaining challenges lie in defining suitable study populations, surrogate outcomes and pivotal long-term, clinically relevant trial endpoints.

U2 - 10.1038/s41584-019-0174-1

DO - 10.1038/s41584-019-0174-1

M3 - Comment/debate

C2 - 30733580

VL - 15

SP - 133

EP - 135

JO - Nature Reviews. Rheumatology

JF - Nature Reviews. Rheumatology

SN - 1759-4790

IS - 3

ER -